SG11202001068YA - Compositions and methods for treatment of atopic dermatitis and treatment selection - Google Patents
Compositions and methods for treatment of atopic dermatitis and treatment selectionInfo
- Publication number
- SG11202001068YA SG11202001068YA SG11202001068YA SG11202001068YA SG11202001068YA SG 11202001068Y A SG11202001068Y A SG 11202001068YA SG 11202001068Y A SG11202001068Y A SG 11202001068YA SG 11202001068Y A SG11202001068Y A SG 11202001068YA SG 11202001068Y A SG11202001068Y A SG 11202001068YA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- compositions
- methods
- atopic dermatitis
- selection
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762546210P | 2017-08-16 | 2017-08-16 | |
PCT/IB2018/056131 WO2019035005A1 (en) | 2017-08-16 | 2018-08-15 | Compositions and methods for treatment of atopic dermatitis and treatment selection |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202001068YA true SG11202001068YA (en) | 2020-03-30 |
Family
ID=63686016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202001068YA SG11202001068YA (en) | 2017-08-16 | 2018-08-15 | Compositions and methods for treatment of atopic dermatitis and treatment selection |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210148910A1 (en) |
EP (1) | EP3669004A1 (en) |
JP (1) | JP2020531439A (en) |
KR (1) | KR20200040803A (en) |
CN (1) | CN110997939A (en) |
AU (1) | AU2018318435A1 (en) |
CA (1) | CA3071783A1 (en) |
EA (1) | EA202090427A1 (en) |
IL (1) | IL272646A (en) |
MA (1) | MA51647A (en) |
SG (1) | SG11202001068YA (en) |
WO (1) | WO2019035005A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4103605A1 (en) * | 2020-02-13 | 2022-12-21 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
TW202229339A (en) * | 2020-12-03 | 2022-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Antibody binding to thymic stromal lymphopoietin and application thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
SE462454B (en) | 1988-11-10 | 1990-06-25 | Pharmacia Ab | METHOD FOR USE IN BIOSENSORS |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
NZ516848A (en) | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
CA2323638A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
AU4025300A (en) | 1999-03-24 | 2000-10-09 | Packard Bioscience Company | Continuous porous matrix arrays |
CA2382545C (en) | 1999-08-27 | 2013-08-13 | Phylos, Inc. | Methods for encoding and sorting in vitro translated proteins |
CA2469403C (en) | 2001-12-05 | 2015-06-02 | Jonathan Mark Boutell | Protein arrays for allelic variants and uses thereof |
CN103278641A (en) * | 2005-10-21 | 2013-09-04 | 株式会社芳珂 | Atopic dermatitis marker and technique of using the same |
EP1981912A2 (en) * | 2006-01-13 | 2008-10-22 | Irm, Llc | Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases |
GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
EP2773774A4 (en) * | 2011-11-03 | 2015-06-10 | Merck Sharp & Dohme | Biomarkers for tslp treatment |
US9790506B2 (en) * | 2013-10-02 | 2017-10-17 | The Regents Of The University Of California | Diagnostic and screening methods for atopic dermatitis |
-
2018
- 2018-08-15 CA CA3071783A patent/CA3071783A1/en not_active Abandoned
- 2018-08-15 EP EP18779017.5A patent/EP3669004A1/en not_active Withdrawn
- 2018-08-15 JP JP2020508478A patent/JP2020531439A/en active Pending
- 2018-08-15 KR KR1020207006863A patent/KR20200040803A/en not_active Application Discontinuation
- 2018-08-15 EA EA202090427A patent/EA202090427A1/en unknown
- 2018-08-15 CN CN201880052371.0A patent/CN110997939A/en active Pending
- 2018-08-15 MA MA051647A patent/MA51647A/en unknown
- 2018-08-15 SG SG11202001068YA patent/SG11202001068YA/en unknown
- 2018-08-15 US US16/637,294 patent/US20210148910A1/en not_active Abandoned
- 2018-08-15 AU AU2018318435A patent/AU2018318435A1/en not_active Abandoned
- 2018-08-15 WO PCT/IB2018/056131 patent/WO2019035005A1/en unknown
-
2020
- 2020-02-12 IL IL272646A patent/IL272646A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN110997939A (en) | 2020-04-10 |
AU2018318435A1 (en) | 2020-04-02 |
WO2019035005A1 (en) | 2019-02-21 |
EA202090427A1 (en) | 2020-06-08 |
JP2020531439A (en) | 2020-11-05 |
CA3071783A1 (en) | 2019-02-21 |
EP3669004A1 (en) | 2020-06-24 |
KR20200040803A (en) | 2020-04-20 |
US20210148910A1 (en) | 2021-05-20 |
MA51647A (en) | 2020-06-24 |
IL272646A (en) | 2020-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL251066A0 (en) | Compositions and methods of use for treating metabolic disorders | |
ZA201700311B (en) | Compositions and methods of use for treating metabolic disorders | |
EP3474879A4 (en) | Compositions and methods of treating melanoma | |
EP3341392A4 (en) | Compositions and methods for treatment of pain | |
IL265473B1 (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
IL272949A (en) | Improved treatment of atopic dermatitis with tradipitant | |
HK1247789A1 (en) | Compositions and methods for treatment of edema | |
HK1257853A1 (en) | Compositions and methods for the treatment and prevention of radiation dermatitis | |
ZA201806503B (en) | Treatment of canine atopic dermatitis | |
HK1250145A1 (en) | Compositions and methods of treating multiple myeloma | |
IL272646A (en) | Compositions and methods for treatment of atopic dermatitis and treatment selection | |
HK1254242A1 (en) | Composition for treatment of inflammatory bowel disease and atopic dermatitis | |
GB201511799D0 (en) | Composition and methods of treatment | |
GB201621737D0 (en) | Compositions and methods of treatment | |
IL273850A (en) | Compositions and methods for treatment of fibrosis | |
EP3247364A4 (en) | Compositions and methods of treating microbes | |
IL248846A0 (en) | Methods and compositions of dasotraline for treatment of adhd | |
GB201605127D0 (en) | Composition and methods of treatment | |
DK3313207T3 (en) | Compositions and methods for the treatment of malnutrition | |
ZA201903005B (en) | Methods and compositions for treating atopic dermatitis | |
EP3294417A4 (en) | Compositions and methods for treatment of glioma | |
EP3280406A4 (en) | Compositions and methods for treatment of movement disorders | |
IL271778A (en) | Methods of treating atopic dermatitis | |
GB201710491D0 (en) | Composition and methods of treatment | |
AU2015903210A0 (en) | Compositions and methods of treatment |